Sugi Predict

Sugi Predict / Targets / NFKBIA

NFKBIA

NF-kappa-B inhibitor alpha · P25963 · NFKBIA on Sugi Atlas →

4,724 patent compounds predicted against NFKBIA, 3,485 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL416275 SCHEMBL416275 1.00 8/20
SCHEMBL463479 SCHEMBL463479 1.00 8/20
SCHEMBL414125 SCHEMBL414125 1.00 7/20
SCHEMBL3817307 SCHEMBL3817307 0.59 6/20
SCHEMBL2055432 SCHEMBL2055432 0.62 5/20
SCHEMBL4470291 SCHEMBL4470291 0.57 5/20
SCHEMBL460773 SCHEMBL460773 1.00 4/20
Physalin B Physalin B (SCHEMBL504410) 1.00 4/20
SCHEMBL5113791 SCHEMBL5113791 0.64 4/20
SCHEMBL1472031 SCHEMBL1472031 0.64 4/20
SCHEMBL819582 SCHEMBL819582 0.63 4/20
SCHEMBL4654523 SCHEMBL4654523 0.45 4/20
SCHEMBL1507919 SCHEMBL1507919 0.76 3/20
SCHEMBL1505430 SCHEMBL1505430 0.71 3/20
SCHEMBL3780950 SCHEMBL3780950 0.67 3/20
SCHEMBL5244488 SCHEMBL5244488 0.62 3/20
SCHEMBL2367581 SCHEMBL2367581 0.61 3/20
SCHEMBL2367583 SCHEMBL2367583 0.58 3/20
SCHEMBL5597436 SCHEMBL5597436 0.56 3/20
SCHEMBL3947043 SCHEMBL3947043 0.55 3/20

Clinical trials — most relevant to NFKBIA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass PHASE2/PHASE3COMPLETED
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk PHASE2/PHASE3COMPLETED
Effect of Salicylate on Glucose Metabolism in Insulin Resistance States PHASE1/PHASE2COMPLETED
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation PHASE2ACTIVE_NOT_RECRUITING
Impact of Colchicine and Low-dose Naltrexone on COVID-19 PHASE2COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients PHASE1/PHASE2COMPLETED
Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy PHASE2COMPLETED
Sodium Bicarbonate in Cardiac Surgery PHASE2COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Effects of Gum Arabic on Metabolic Syndrome Parameters in Postmenopausal Women PHASE2COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma PHASE2COMPLETED
Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot PHASE2COMPLETED
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells PHASE2UNKNOWN
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients nanCOMPLETED
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients nanRECRUITING
Magnesium and Vitamin D Combination for Post-COVID Syndrome nanCOMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Vitamin D With Omega-3 or Metformin in Osteoarthritis nanNOT_YET_RECRUITING
The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients. nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Post-surgery Systemic Inflammation and Neuro-immune Interactions nanCOMPLETED
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis nanUNKNOWN
Effects of Curcumin on Markers of Cardiovascular Risk in Patients With CAD nanWITHDRAWN
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient nanRECRUITING
Mechanisms of Insulin Resistance in Humans nanCOMPLETED
Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease nanUNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NFKBIA binder may also engage these)

ProteinNameSimilarity
Q9Z1E3 — 1.000 Q9Z1E3 →
Q63746 — 1.000 Q63746 →
Q08353 — 0.999 Q08353 →
Q91974 — 0.997 Q91974 →
Q8WXK4 — 0.986 Q8WXK4 →
Q96I34 — 0.985 Q96I34 →
Q63618 — 0.984 Q63618 →
Q8K330 — 0.983 Q8K330 →
Q8TDY4 — 0.983 Q8TDY4 →
Q6NZL6 — 0.983 Q6NZL6 →
Q566C8 — 0.982 Q566C8 →
D4A615 — 0.982 D4A615 →
Q86SG2 — 0.982 Q86SG2 →
P25799 — 0.982 P25799 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.982 landscape →
Q5R7G8 — 0.982 Q5R7G8 →
Q9R117 — 0.982 Q9R117 →
Q9ET47 — 0.982 Q9ET47 →
Q2T9W8 — 0.982 Q2T9W8 →
Q812A3 — 0.982 Q812A3 →
A9JR78 — 0.982 A9JR78 →
Q9D738 — 0.982 Q9D738 →
Q80VA5 — 0.981 Q80VA5 →
Q8BLD6 — 0.981 Q8BLD6 →
Q9Z2R9 — 0.981 Q9Z2R9 →
D3YWQ0 — 0.981 D3YWQ0 →
Q5BIW4 — 0.981 Q5BIW4 →
P98150 — 0.980 P98150 →
Q8BHW9 — 0.980 Q8BHW9 →
O95238 — 0.980 O95238 →